Navigation Links
Tapping the body's own defenses, researchers look to cutting-edge gene therapy for bladder cancer
Date:1/10/2012

CLEVELAND -- Bladder cancer, most frequently caused by smoking and exposure to carcinogens in the workplace, is one of the top 10 most common forms of cancer in men and women in the U.S. More than 70 percent of bladder cancers are diagnosed in stage T1 or less and have not invaded the muscle layer. At these early stages, standard treatment is surgery (transurethral resection) and the burning away of tumors with high energy electricity (fulguration). Many patients also may receive subsequent intravesical chemotherapy because there is often a high-risk for cancer recurrence.

The prognosis for recurrent cancer is poor, which drives clinician-scientists like William Larchian, MD, Urologic Oncologist, University Hospitals Urology Institute at University Hospitals Case Medical Center, and Associate Professor of Surgery, Case Western Reserve University School of Medicine, and his colleagues to develop an immunotherapy for bladder cancer that will stimulate the body's own natural defense mechanisms to cure the disease and prevent recurrence.

"What is interesting is that our bodies are capable of identifying, responding to and killing tumor cells naturally," explained Dr. Larchian. "We are developing a vaccination system to enhance this response and drive an effective immune response against existing and future bladder tumor cells in patients diagnosed with bladder cancer."

IL-2, a cytokine-signaling molecule, stimulates the T-cell immune response to cancer cells in the bladder. Dr. Larchian and his colleagues have developed a system that reliably introduces multiple copies of IL-2 DNA into bladder cancer cells.

"This method allows for more gene copies to enter the cells," he said, "and we are able to see higher rates of transfection compared to retroviral methods."

The enhanced IL-2 protein expression has been shown to successfully stimulate T-cell response and eliminate bladder tumors in a mouse model, particularly when
'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Tapping into plants is the key to combat climate change, says scientist
2. Researchers discover novel anti-viral immune pathway in the mosquito
3. MU researchers find unique protein organization in arteries associated with cardiovascular disease
4. Frogs use calls to find mates with matching chromosomes, University of Missouri researchers find
5. Viagra against heart failure: Researchers at the RUB and from Rochester throw light on the mechanism
6. DOE researchers achieve important genetic breakthroughs to help develop cheaper biofuels
7. Drugs used to overcome cancer may also combat antibiotic resistance: McMaster researchers
8. Researchers develop new method of cleaning toxins from the oilsands
9. Researchers discover a way to significantly reduce the production costs of fuel cells
10. San Diego Zoo researchers contribute to project using mummy DNA to differentiate croc species
11. Researchers create living neon signs composed of millions of glowing bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... The microscopic phytoplankton Aureococcus anophagefferens , which causes ... to be a fierce competitor. In the first ... found that Aureococcus , unique gene complement allows ... human-modified ecosystems, which could help explain the global increases ...
... pathways that are mutated in many forms of cancer, ... disease including hypertrophic cardiomyopathy (HCM), a thickening of ... sudden death in children and young adults , have ... in the lab. In two separate but ...
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
Cached Biology News:First harmful algal bloom species genome sequenced 2First harmful algal bloom species genome sequenced 3Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , NATICK, Mass., Sept. 14 Boston ... that it has entered into a co-marketing agreement with ... testing solutions for urinary incontinence. Bladder Health Network ... supplies and results analysis, helping to ensure that physicians ...
... 14 Health Robotics today reported,that Dr M Group has ... of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, Vietnam, and ... on 2 companies in the field of I.V.,Robotics, the doubts ... announced multi-year delays in bringing their robot to first,hospital,s use], ...
... , , , ... announced that the results of a comprehensive review of safety data from ... Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, ... risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 2Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 3Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 5Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 6Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 7Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 8
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: